Nastya Kassir

520 total citations
46 papers, 400 citations indexed

About

Nastya Kassir is a scholar working on Epidemiology, Oncology and Hematology. According to data from OpenAlex, Nastya Kassir has authored 46 papers receiving a total of 400 indexed citations (citations by other indexed papers that have themselves been cited), including 12 papers in Epidemiology, 11 papers in Oncology and 11 papers in Hematology. Recurrent topics in Nastya Kassir's work include Antibiotics Pharmacokinetics and Efficacy (7 papers), Inflammatory Bowel Disease (6 papers) and Renal Transplantation Outcomes and Treatments (5 papers). Nastya Kassir is often cited by papers focused on Antibiotics Pharmacokinetics and Efficacy (7 papers), Inflammatory Bowel Disease (6 papers) and Renal Transplantation Outcomes and Treatments (5 papers). Nastya Kassir collaborates with scholars based in United States, Canada and Switzerland. Nastya Kassir's co-authors include Yves Théorêt, Samer Mouksassi, Catherine Litalien, Julie Autmizguine, Athena F. Zuppa, Jeffrey S. Barrett, Mike A. Royal, Gregory B. Hammer, Jean‐Francois Marier and Anne‐Laure Lapeyraque and has published in prestigious journals such as Blood, Gastroenterology and Cancer Research.

In The Last Decade

Nastya Kassir

43 papers receiving 386 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Nastya Kassir United States 13 84 82 80 72 69 46 400
Grant Langdon United Kingdom 12 71 0.8× 136 1.7× 90 1.1× 167 2.3× 127 1.8× 28 736
I. Buggia Italy 5 74 0.9× 49 0.6× 88 1.1× 40 0.6× 48 0.7× 7 356
Thao Doan United States 13 71 0.8× 47 0.6× 24 0.3× 99 1.4× 80 1.2× 35 543
Marie‐Claude Gagnieu France 19 102 1.2× 71 0.9× 43 0.5× 273 3.8× 169 2.4× 63 889
Meagan J. Bemer United States 10 55 0.7× 68 0.8× 196 2.5× 35 0.5× 47 0.7× 16 363
Herman Veenhof Netherlands 12 109 1.3× 160 2.0× 156 1.9× 32 0.4× 68 1.0× 14 618
P. M. Hooymans Netherlands 15 123 1.5× 23 0.3× 111 1.4× 214 3.0× 78 1.1× 35 875
Rogier R. Press Netherlands 12 166 2.0× 36 0.4× 54 0.7× 61 0.8× 66 1.0× 16 506
John Mondick United States 15 116 1.4× 39 0.5× 71 0.9× 100 1.4× 101 1.5× 32 598
Camille Tron France 16 149 1.8× 71 0.9× 25 0.3× 130 1.8× 75 1.1× 46 568

Countries citing papers authored by Nastya Kassir

Since Specialization
Citations

This map shows the geographic impact of Nastya Kassir's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Nastya Kassir with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Nastya Kassir more than expected).

Fields of papers citing papers by Nastya Kassir

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Nastya Kassir. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Nastya Kassir. The network helps show where Nastya Kassir may publish in the future.

Co-authorship network of co-authors of Nastya Kassir

This figure shows the co-authorship network connecting the top 25 collaborators of Nastya Kassir. A scholar is included among the top collaborators of Nastya Kassir based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Nastya Kassir. Nastya Kassir is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Ma, Fang, Yoen‐Ju Son, Tom De Bruyn, et al.. (2025). Mechanistic Physiologically Based Pharmacokinetic Modeling of Dry Powder and Nebulized Formulations of Orally Inhaled TMEM16A Potentiator GDC‐6988. CPT Pharmacometrics & Systems Pharmacology. 14(6). 1087–1097.
2.
3.
Kassir, Nastya, et al.. (2024). Exposure‐Response Relationships for Pralsetinib in Patients with RET‐Altered Thyroid Cancer or RET Fusion‐Positive Nonsmall Cell Lung Cancer. The Journal of Clinical Pharmacology. 64(6). 685–696. 2 indexed citations
4.
Bowman, Christine M., Michael Dolton, Fang Ma, et al.. (2024). Understanding CYP3A4 and P-GP mediated drug-drug interactions through PBPK modeling - case example of pralsetinib. Drug Metabolism and Pharmacokinetics. 55. 100969–100969. 2 indexed citations
5.
Veerabathiran, Ramakrishnan, Brendan C. Bender, Jurgen Langenhorst, et al.. (2024). Semorinemab Pharmacokinetics and The Effect on Plasma Total Tau Pharmacodynamics in Clinical Studies. The Journal of Prevention of Alzheimer s Disease. 11(5). 1241–1250. 3 indexed citations
6.
Doz, François, Michela Casanova, Kyung‐Nam Koh, et al.. (2024). Abstract CT039: Alectinib in children and adolescents with solid or CNS tumors harboring ALK-fusions: Data from the iMATRIX Alectinib Phase I/II open-label, multi-center study. Cancer Research. 84(7_Supplement). CT039–CT039. 1 indexed citations
7.
8.
Yu, Yanke, Michael E. Rothenberg, Han Ting Ding, et al.. (2023). Population pharmacokinetics and pharmacodynamics of efmarodocokin alfa (IL-22Fc). Journal of Pharmacokinetics and Pharmacodynamics. 51(2). 141–153. 2 indexed citations
9.
10.
11.
Kassir, Nastya, et al.. (2023). External validation of a tumor growth inhibition-overall survival model in non-small-cell lung cancer based on atezolizumab studies using alectinib data. Cancer Chemotherapy and Pharmacology. 92(3). 205–210. 4 indexed citations
12.
Langenhorst, Jurgen, et al.. (2023). A disease model predicting placebo response and remission status of patients with ulcerative colitis using modified Mayo score. Clinical and Translational Science. 16(11). 2310–2322. 3 indexed citations
13.
Lu, Tong, Siv Jönsson, Jakob Ribbing, et al.. (2022). Population pharmacokinetic analysis of etrolizumab in patients with moderately‐to‐severely active ulcerative colitis. CPT Pharmacometrics & Systems Pharmacology. 11(9). 1244–1255. 5 indexed citations
14.
Kassir, Nastya, Jurgen Langenhorst, Jakob Ribbing, et al.. (2022). Exposure‐response relationships of etrolizumab in patients with moderately‐to‐severely active ulcerative colitis. CPT Pharmacometrics & Systems Pharmacology. 11(9). 1234–1243. 5 indexed citations
15.
Okubo, Yukari, Mamitaro Ohtsuki, Mayumi Komine, et al.. (2021). Population pharmacokinetic and exposure–response analysis of apremilast in Japanese subjects with moderate to severe psoriasis. The Journal of Dermatology. 48(11). 1652–1664. 3 indexed citations
16.
Wang, Diane D., Yanke Yu, Nastya Kassir, et al.. (2017). The Utility of a Population Approach in Drug–Drug Interaction Assessments: A Simulation Evaluation. The Journal of Clinical Pharmacology. 57(10). 1268–1278. 7 indexed citations
17.
Ouellet, Danièle, Nastya Kassir, Samer Mouksassi, et al.. (2016). Population pharmacokinetics and exposure–response of trametinib, a MEK inhibitor, in patients with BRAF V600 mutation-positive melanoma. Cancer Chemotherapy and Pharmacology. 77(4). 807–817. 42 indexed citations
18.
Lapeyraque, Anne‐Laure, Nastya Kassir, Yves Théorêt, et al.. (2014). Conversion from twice- to once-daily tacrolimus in pediatric kidney recipients: a pharmacokinetic and bioequivalence study. Pediatric Nephrology. 29(6). 1081–1088. 13 indexed citations
19.
Leeds, Janet M., Nathalie Gosselin, Samer Mouksassi, et al.. (2012). Pharmacokinetic and Pharmacodynamic Modeling To Determine the Dose of ST-246 To Protect against Smallpox in Humans. Antimicrobial Agents and Chemotherapy. 57(3). 1136–1143. 19 indexed citations
20.
Delaloye, Jean‐Romain, Nastya Kassir, Anne‐Laure Lapeyraque, et al.. (2011). Limited Sampling Strategies for Monitoring Tacrolimus in Pediatric Liver Transplant Recipients. Therapeutic Drug Monitoring. 33(4). 380–386. 8 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Grant Langdon Breakdown of academic impact, for papers by I. Buggia Breakdown of academic impact, for papers by Thao Doan Breakdown of academic impact, for papers by Marie‐Claude Gagnieu Breakdown of academic impact, for papers by Meagan J. Bemer Breakdown of academic impact, for papers by Herman Veenhof Breakdown of academic impact, for papers by P. M. Hooymans Breakdown of academic impact, for papers by Rogier R. Press Breakdown of academic impact, for papers by John Mondick Breakdown of academic impact, for papers by Camille Tron
Rankless by CCL
2026